Glycogen storage disease type V
Last updated 18 Aug 2020
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
Glycogen storage disease type V (also known as GSDV or McArdle disease) is an inherited disorder caused by an inability to break down a complex sugar called glycogen in muscle cells. A lack of glycogen breakdown interferes with the function of muscle cells.
Video picks for Genetic conditionsVideo library
Description
Glycogen storage disease type V (also known as GSDV or McArdle disease) is an inherited disorder caused by an inability to break down a complex sugar called glycogen in muscle cells. A lack of glycogen breakdown interferes with the function of muscle cells.
People with GSDV typically experience fatigue, muscle pain, and cramps during the first few minutes of exercise (exercise intolerance). Exercise such as weight lifting or jogging usually triggers these symptoms in affected individuals. The discomfort is generally alleviated with rest. If individuals rest after brief exercise and wait for their pain to go away, they can usually resume exercising with little or no discomfort (a characteristic phenomenon known as "second wind").
Prolonged or intense exercise can cause muscle damage in people with GSDV. About half of people with GSDV experience breakdown of muscle tissue (rhabdomyolysis). In severe episodes, the destruction of muscle tissue releases a protein called myoglobin, which is filtered through the kidneys and released in the urine (myoglobinuria). Myoglobin causes the urine to be red or brown. This protein can also damage the kidneys, and it is estimated that half of those individuals with GSDV who have myoglobinuria will develop life-threatening kidney failure.
The signs and symptoms of GSDV can vary significantly in affected individuals. The features of this condition typically begin in a person's teens or twenties, but they can appear anytime from infancy to adulthood. In most people with GSDV, the muscle weakness worsens over time; however, in about one-third of affected individuals, the muscle weakness is stable. Some people with GSDV experience mild symptoms such as poor stamina; others do not experience any symptoms.
Inheritance patterns
The source lists the following possible inheritance patterns: Autosomal recessive. More than one pattern can apply in different cases.
Related genes
Other names
Glycogen storage disease type 5
Glycogenosis 5
GSD type V
GSD V
McArdle disease
McArdle syndrome
McArdle type glycogen storage disease
McArdle's disease
Muscle glycogen phosphorylase deficiency
Muscle phosphorylase deficiency
Myophosphorylase deficiency
PYGM deficiency
Patient picks for Genetic conditions

Children's health
Glycogen storage disorders
Glycogen storage disorders are a group of inherited diseases. They result from a problem with one of the proteins (known as enzymes) involved in the conversion of glucose to glycogen, or the breakdown of glycogen back into glucose. They mostly tend to affect your liver and muscles. Most are diagnosed in childhood. Symptoms include weakness, tiredness and low blood sugar levels. Newer treatment possibilities provide hope for an improved outlook (prognosis). Most people with a glycogen storage disorder respond well to treatment. However, type II (infantile Pompe's disease) can be difficult to treat and can affect life expectancy.
by Dr Roger Henderson, MBBS

Kidney and urinary tract
IgA nephropathy
IgA nephropathy is a condition in which a protein causes damage to the kidneys. The protein is called immunoglobulin A or IgA. Nephropathy means an illness that damages the kidney.
by Dr Colin Tidy, MRCGP

Diabetes
MHRA approves teplizumab to delay progression of type 1 diabetes
Teplizumab (Tzield) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to help delay the onset of Stage 3 type 1 diabetes (T1D). Read on to see what this means if you are prescribed teplizumab and what it does for you.
by Lawrence Higgins

Diabetes
Changes in type 2 diabetes care - what it means for you
If you are living with type 2 diabetes your treatment may soon change to be tailored around you and your specific needs - which will help improve your long-term health. Read on to find out what the changes are and what they mean for you.
by Lawrence Higgins

Diabetes
Video: How do you know if you have type 2 diabetes?
There are a lot of symptoms involved with type 2 diabetes, some of which may be mistaken for something else. Our experts look at what you need to look out for, and answer some other common questions about this widespread condition.
by Dr Partha Kar, FRCP

General health
Asbestos-related diseases
People exposed to asbestos can develop diseases in later life. These most commonly affect the lungs but can also affect the lining of the tummy (abdomen). Some conditions - for example, mesothelioma or lung cancer - are more serious than others. This leaflet gives a brief overview of the diseases that are related to having an exposure to asbestos in the past.
by Dr Louise Newson, MRCGP
Related patient information and medicines

Patient information leaflet
Glycogen storage disorders
Glycogen storage disorders are a group of inherited diseases. They result from a problem with one of the proteins (known as enzymes) involved in the conversion of glucose to gly... Glycogen storage disorders are a group of inherited diseases that result from a lack of, or abnormal functioning of, one of the proteins (enzymes) involved in the.

Patient information leaflet
Non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) describes a range of conditions caused by a build-up of fat within liver cells. It is very common and in many cases is linked to being obese or overweight. Much of the food we eat is broken down by the body into... This is what our bodies use for energy. Glucose can't be stored so it is turned into a.

Patient information leaflet
Diabetic kidney disease
Diabetic kidney disease is a complication that occurs in some people with diabetes. Treatment aims to prevent or delay the progression of the disease. Also, it aims to reduce the risk of developing cardiovascular diseases such as heart attack and stroke which are much more common than average in people with this disease. What is diabetic kidney.

Patient information leaflet
IgA nephropathy
IgA nephropathy is a condition in which a protein causes damage to the kidneys. The protein is called immunoglobulin A or IgA. Nephropathy means an illness that damages the kidney. The main job of the kidneys is to clear waste materials from the body and maintain a normal balance of fluids and chemicals in the body. The kidneys also have other.

Patient information leaflet
Wilson's disease
Wilson's disease is a genetic disorder in which copper builds up in the body, mainly in the liver and brain. Without any treatment, the build-up of copper can cause serious symptoms. Treatment is with medication to remove the excess copper and/or to prevent a further build-up of copper. What is Wilson's disease. Wilson's disease is a condition.

Patient information leaflet
Diet in chronic kidney disease
Chronic kidney disease (CKD) is a common long-term condition where the kidneys aren't working as well as they should be. There are some dietary choices that are recommended for people with early CKD. People with more advanced CKD may be advised to follow a special diet, usually with the support of a specialist dietician. It's important for.
Further reading and references
- Glycogen storage disease type V; MedlinePlus, National Library of Medicine.
- Aquaron R, Berge-Lefranc JL, Pellissier JF, Montfort MF, Mayan M, Figarella-Branger D, Coquet M, Serratrice G, Pouget J. Molecular characterization of myophosphorylase deficiency (McArdle disease) in 34 patients from Southern France: identification of 10 new mutations. Absence of genotype-phenotype correlation. Neuromuscul Disord. 2007 Mar;17(3):235-41. doi: 10.1016/j.nmd.2006.12.014. Epub 2007 Feb 26.
- Bruno C, Cassandrini D, Martinuzzi A, Toscano A, Moggio M, Morandi L, Servidei S, Mongini T, Angelini C, Musumeci O, Comi GP, Lamperti C, Filosto M, Zara F, Minetti C. McArdle disease: the mutation spectrum of PYGM in a large Italian cohort. Hum Mutat. 2006 Jul;27(7):718. doi: 10.1002/humu.9434.
- Deschauer M, Morgenroth A, Joshi PR, Glaser D, Chinnery PF, Aasly J, Schreiber H, Knape M, Zierz S, Vorgerd M. Analysis of spectrum and frequencies of mutations in McArdle disease. Identification of 13 novel mutations. J Neurol. 2007 Jun;254(6):797-802. doi: 10.1007/s00415-006-0447-x. Epub 2007 Apr 3.
- Gurgel-Giannetti J, Nogales-Gadea G, van der Linden H Jr, Bellard TM, Brasileiro Filho G, Giannetti AV, de Castro Concentino EL, Vainzof M. Clinical and molecular characterization of McArdle's disease in Brazilian patients. Neuromolecular Med. 2013 Sep;15(3):470-5. doi: 10.1007/s12017-013-8233-2. Epub 2013 May 8.
- Lucia A, Nogales-Gadea G, Perez M, Martin MA, Andreu AL, Arenas J. McArdle disease: what do neurologists need to know? Nat Clin Pract Neurol. 2008 Oct;4(10):568-77. doi: 10.1038/ncpneuro0913.
- Lucia A, Ruiz JR, Santalla A, Nogales-Gadea G, Rubio JC, Garcia-Consuegra I, Cabello A, Perez M, Teijeira S, Vieitez I, Navarro C, Arenas J, Martin MA, Andreu AL. Genotypic and phenotypic features of McArdle disease: insights from the Spanish national registry. J Neurol Neurosurg Psychiatry. 2012 Mar;83(3):322-8. doi: 10.1136/jnnp-2011-301593. Epub 2012 Jan 16.
- Rubio JC, Garcia-Consuegra I, Nogales-Gadea G, Blazquez A, Cabello A, Lucia A, Andreu AL, Arenas J, Martin MA. A proposed molecular diagnostic flowchart for myophosphorylase deficiency (McArdle disease) in blood samples from Spanish patients. Hum Mutat. 2007 Feb;28(2):203-4. doi: 10.1002/humu.9474.
Share your thoughts or experiences with others in our patient communities.
Sign up to the Patient newsletter
Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.

